Tydo-Stimulant

Project "Tydo-Stimulant" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

As the global population grows, there is an increasing need to secure food production in a sustainable manner. One of the most promising innovations in agriculture, is the use of plant-beneficial microorganisms and substances known as biostimulants. The use of biostimulants in has demonstrated great potential but current methods of biostimulant production yield low levels of biostimulant (grams), which makes widespread adoption difficult. Biostimulant producing companies currently face difficulties in extracting policosanols and TRIA from natural sources, in large quantities and at reasonable production costs. For industrial production of policosanols, only sugar cane, bees wax and fabaceae have proved promising. Sugar cane contains very low amounts of TRIA and the supercritical CO2 used to extract natural triacontanol content from Fabaceae is very expensive. The conventional extraction process from beeswax takes several hours and is resource-intensive. In response, Tydock Pharma, is upscaling an efficient biostimulant extraction process and a new potent biostimulant blend from beeswax. We are working in collaboration with pharmaceutical, agronomy, and research institutions to ensure success upscaling of our production process. Our production process is green, with no toxic by-products and has the potential to increase biostimulant production from current yields of a few grams to kilograms per cycle, enabling the universal application of biostimulants in increasing global food production, naturally. The production cycle is 20 minutes, which is more than 12 times faster than conventional production methods. This enables us to produce 98% more biostimulant than our competitors. We expect average cumulative profits of 15.2 million. A ROI of €10.9 per euro invested and 7 new employees for the first 5 years of commercialisation. We anticipate that by year 5, we would have captured 3.6% of the European biostimulant market share.